Globeflex Capital’s 2seventy bio TSVT Stock Holding History

Globeflex Capital’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,778	Closed	-$119K	–	501
2023 Q2	$119K	Buy	+11,778	New	+$125K	0.01%	363

Other funds holding TSVT

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Globeflex Capital's TSVT Position: Q3 2023 in Review

Globeflex Capital sold out of 2seventy bio (TSVT) in Q3 2023, closing a stake of 11,778 shares — an estimated $119K sold.

Globeflex Capital first reported a position in TSVT in Q2 2023 and held it in 1 quarter. The position peaked at $119K in Q2 2023. 145 funds tracked by Wall St. Rank hold TSVT as of Q3 2023.

Globeflex Capital reported no remaining 2seventy bio position as of Q3 2023 after selling out during the quarter.
Globeflex Capital sold 11,778 2seventy bio shares in Q3 2023, an estimated $119K.
Globeflex Capital first reported a position in 2seventy bio in Q2 2023 and held it in 1 quarter.
Globeflex Capital's 2seventy bio position peaked at $119K in Q2 2023.
145 funds tracked by Wall St. Rank held 2seventy bio as of Q3 2023.

Based on Globeflex Capital's 13F filing for Q3 2023, filed 13 Nov 2023.